UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INTAS PHARMACEUTICALS LTD
Petitioner,

v.

ATOSSA THERAPEUTICS, INC.
Patent Owner

Case IPR2025-00799
Patent 11,261,151

DECLARATION OF HAYLEY R. LEBLANC IN SUPPORT OF PATENT OWNER'S UNOPPOSED MOTION FOR *PRO HAC VICE* ADMISSION

Atossa Therapeutics, Inc. Exhibit 2029
Intas Pharms Ltd. v. Atossa Therapeutics, Inc.
IPR2025-00799
Page 00001

Pursuant to 37 C.F.R. § 1.68, I, Hayley R. LeBlanc, declare as follows:

1. I am a member in good standing of the bar of the District of Columbia. I have personal knowledge of the facts set forth in this Declaration. All statements herein made of my own knowledge are true and all statements made on information and belief are believed to be true.

2. I have never been suspended or disbarred from practice before any court or administrative body.

3. I have never had any application for admission to practice before any court or administrative body ever denied.

4. I have never had any sanctions or contempt citations imposed against me by any court or administrative body.

5. I have read and will comply with the Patent Trial and Appeal Board Consolidated Trial Practice Guide and the Board's Rules for Practice for Trials set forth in Part 42 of Title 37 of the Code of Federal Regulations.

6. I agree to be subject to the USPTO Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 et seq., and to disciplinary jurisdiction under 37 C.F.R. § 11.19(a).

7. In the last three years, I have not applied to appear *pro hac vice* in any proceedings before the United States Patent and Trademark Office.

Atossa Therapeutics, Inc. Exhibit 2029
Intas Pharms Ltd. v. Atossa Therapeutics, Inc.
IPR2025-00799
Page 00002

8. I have an established familiarity with U.S. Patent No. 11,261,151 (the "'151 Patent"), the patented technology, and the specific subject matter in this proceeding. Since April 2025, I have been heavily involved with this proceeding, including in the analysis of invalidity issues raised by Intas. I have substantively participated in the analysis of the Petition, analysis of the Institution Decision, and Preparation of Patent Owner's Response, and am thus familiar with the filings and various issues raised in this proceeding.

9. I am an experienced litigation attorney, and I clerked for the Patent Trial and Appeal Board for 1 year and since then, have been practicing law for over 1 year. During this time, I have worked on various aspects of post-grant proceedings and patent litigation before district courts.

10. I have been warned that willful false statements and the like are punishable by fine or imprisonment, or both (18 U.S.C. §1001) and may jeopardize the validity of the patent at issue in this proceeding.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on December 24, 2025 at Washington, DC.

/Hayley R. LeBlanc/
Hayley R. LeBlanc

Atossa Therapeutics, Inc. Exhibit 2029
Intas Pharms Ltd. v. Atossa Therapeutics, Inc.
IPR2025-00799
Page 00003